Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.78 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4306484 | 0.99 | HTR6 (0.77) | HTR6USP2MET | |
| SCHEMBL6377020 | 0.88 | HTR6 (0.73) | HTR6 | |
| SCHEMBL1136472 | 0.84 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4316003 | 0.84 | HTR6 (1.00) | HTR6 | |
| Hydrochloric Acid SCHEMBL6518347 | 0.83 | HTR6 (0.98) | HTR6 | |
| SCHEMBL5698329 | 0.83 | HTR6 (0.85) | HTR6 | |
| SCHEMBL4312550 | 0.83 | HTR6 (0.82) | HTR6 | |
| Hydrochloric Acid SCHEMBL4319160 | 0.82 | HTR6 (0.80) | HTR6 | |
| SCHEMBL4308645 | 0.82 | HTR6 (0.70) | HTR6 | |
| Hydrochloric Acid SCHEMBL6381521 | 0.81 | HTR6 (0.62) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | claimed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885USP2 2559/4885MET 2487/4885 |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | HTR6 1/4885USP2 4764/4885MET 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.